Protein kinase C inhibitors: a patent review (2008 – 2009)

Bibliography

• Newton AC. Protein kinase C. Structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001;101:2353-64
   PubMed Web of Science ®Google Scholar
• Newton AC. Protein kinase C family. Enc Biol Chem 2004;3:523-6
   Google Scholar
• Katz EZ, Glazer RI. Phospholipid and Ca2+-dependent protein kinase activity and protein phosphorylation patterns in the differentiation of human promyelocytic leukemia cell line HL-60. Cancer Res 1985;45:5159-64
   PubMed Web of Science ®Google Scholar
• Mumby MC, Walter G. Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth. Physiol Rev 1993;73:673-99
   PubMed Web of Science ®Google Scholar
• Inoue M, Kishimoto A, Takai Y, Nishizuka Y. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. J Biol Chem 1977;252:7610-16
   PubMed Web of Science ®Google Scholar
• Marquez VE, Blumberg PM. Synthetic diacylglycerols (DAG) and DAG-Lactones as activators of protein kinase C (PKC). Acc Chem Res 2003;36:434-43
   PubMed Web of Science ®Google Scholar
• Rui L, Archer SF, Argetsinger LS, et al. Platelet-derived growth factor and lysophosphatidic acid inhibit growth hormone binding and signaling via a protein kinase C-dependent pathway. J Biol Chem 2000;275:2885-92
   PubMed Web of Science ®Google Scholar
• Goel G, Makkar HPS, Francis G, Becker K. Phorbol esters: structure, biological activity, and toxicity in animals. Int J Toxicol 2007;26:279-88
   PubMed Web of Science ®Google Scholar
• Sansbury M, Johnson EW, Qi C, et al. Effects of protein kinase C activators on phorbol ester-sensitive and -resistant EL4 thymoma cells heather. Carcinogenesis 1997;18:1817-24
   PubMed Web of Science ®Google Scholar
• Fry DW, Bedford DC, Harvey PH, et al. Cell cycle and biochemical effects of PD 0183812- a potent inhibitor of the cyclin D-dependent kinases cdk4 and cdk6. J Biol Chem 2001;276:16617-23
   PubMed Web of Science ®Google Scholar
• Salles B, Calsou P, Frit P, Muller C. The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy. Pathol Biol 2006;54:185-93
   PubMedGoogle Scholar
• Hulver MW, Dohm GL. The molecular mechanism linking muscle fat accumulation to insulin resistance. Camb Univ Press 2004;63:375-80
   Google Scholar
• Sobhia ME, Grewal BK, Bhat J, et al. Protein kinase C βII in diabetic complications: survey of structural, biological and computational studies. Expert Opin Ther Targets 2012;16:325-44
   PubMed Web of Science ®Google Scholar
• Newton AC. Regulation of ABC kinases by phosphorylation: protein kinase C as paradigm. Biochem J 2003;370:361-71
   PubMed Web of Science ®Google Scholar
• Newton AC. The C1 and C2 domains of protein kinase C are independent membrane targeting modules, with specificity for phosphatidylserine conferred by the C domain. Biochemistry 2000;39:11360-9
   PubMed Web of Science ®Google Scholar
• William CW, Wasiuddin AK, Istvan M, et al. Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J Cell Biol 1992;117:121-33
   PubMed Web of Science ®Google Scholar
• Harris W, Wilkinson SE, Nixon JS. Recent developments in protein kinase C inhibitors. Expert Opin Ther Patents 1997;7:63-8
   Web of Science ®Google Scholar
• Shiying L, Yuyang J, Jian C, et al. Inhibitors of protein kinase C. Chin Sci Bull 2005;50:1293-304
   Google Scholar
• Lucilia S, Paula F, Eugenia P, Jorge G. Isoform-selectivity of PKC inhibitors acting at the regulatory and catalytic domain of mammalian PKC-α, -βI,-δ, -η and –ζ. J Enzyme Inhib Med Chem 2003;18:475-83
   PubMed Web of Science ®Google Scholar
• Davis PD, Hill CH, Lawton G, et al. Inhibitors of protein kinase C. 1. 2, 3-bisarylmaleimides. J Med Chem 1992;35:177-84
   PubMed Web of Science ®Google Scholar
• Li PF, Maasch C, Haller H, et al. Requirement for protein kinase C in reactive oxygen species–induced apoptosis of vascular smooth muscle cells. Circulation 1999;100:967-73
   PubMed Web of Science ®Google Scholar
• Dunai ZA, Imre G, Barna G, et al. Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells. PLoS One 2012;7:1-14
   Web of Science ®Google Scholar
• Wagner J, Von MP, Sedrani RJ, et al. Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. Med Chem 2009;52:6193-6
   Web of Science ®Google Scholar
• Vignot S, Soria JC, Spano JP. Protein kinases C: a new cytoplasmic target. Cancer 2008;95:683-9
   Web of Science ®Google Scholar
• Wang W, Song N, Zhang H. 6-Hydroxydopamine upregulates iron regulatory protein 1 by activating certain protein kinase C isoforms in the dopaminergic MES23.5 cell line. Int J Biochem Cell Biol 2012;44:1987-92
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Akisue T, Kishimoto K, et al. Inhibition of PKC alpha activation in human bone and soft tissue sarcoma cells by the selective PKC inhibitor PKC412. Anticancer Res 2008;28:825-32
   PubMed Web of Science ®Google Scholar
• Takahashi I, Asano K, Kawamoto I, et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. I. Screening, producing organism and fermentation. J Antibiot 1989;42:564-70
   PubMed Web of Science ®Google Scholar
• Wolf M, Baggiolini M. The protein kinase inhibitor staurosporine, like phorbol esters, induces the association of protein kinase C with membranes. Biochem Biophys Res Commun 1988;154:1273-9
   PubMed Web of Science ®Google Scholar
• Connelly KA, Kelly DJ, Zhang Y, et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2009;2:129-37
   PubMed Web of Science ®Google Scholar
• Gschwendt M, Müller HJ, Kielbassa K, et al. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 1994;199:93-8
   PubMed Web of Science ®Google Scholar
• Fabbro D, Ruetz S, Bodis S, et al. PKC412–a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28
   PubMedGoogle Scholar
• Jasinski P, Zwolak P, Terai K, et al. PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis. Invest New Drugs 2011;29:33-40
   PubMed Web of Science ®Google Scholar
• Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001;10:2117-40
   PubMed Web of Science ®Google Scholar
• Shen GX. Selective protein kinase C inhibitors and their applications. Curr Drug Targets Cardiovasc Haematol Disord 2003;3:301-7
   PubMedGoogle Scholar
• Bishop WR, Petrin J, Wang L, et al. Inhibition of protein kinase C by the tyrosine kinase inhibitor erbstatin. Biochem Pharmacol 1990;40:2129-35
   PubMed Web of Science ®Google Scholar
• Willey CD, Xiao D, Tu T, et al. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation. Int J Radiat Oncol Biol Phys 2010;77:1518-26
   PubMed Web of Science ®Google Scholar
• Keenan C, Goode N, Pears C. Isoform specificity of activators and inhibitors of protein kinase C gamma and delta. FEBS Lett 1997;415:101-8
   PubMed Web of Science ®Google Scholar
• Gopalakrishna R, Chen ZH, Gundimeda U. Irreversible oxidative inactivation of protein kinase C by photosensitive inhibitor calphostin C. FEBS Lett 1992;314:149-54
   PubMed Web of Science ®Google Scholar
• Yang EB, Zhang K, Cheng LY, et al. Butein, a specific protein tyrosine kinase inhibitor. Biochem Biophys Res Commun 1998;245:435-8
   PubMed Web of Science ®Google Scholar
• Kortmansky J, Schwartz GK. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol 2010;33:121-4
   PubMed Web of Science ®Google Scholar
• Kortmansky J, Schwartz GK. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest 2003;21:924-36
   PubMed Web of Science ®Google Scholar
• Tatsuda Y, Iguchi K, Usui S, et al. Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells. Eur J Pharmacol 2010;627:348-53
   PubMed Web of Science ®Google Scholar
• McGill JB, King GL, Berg PH, et al. Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. Expert Opin Drug Saf 2006;5:835-45
   PubMed Web of Science ®Google Scholar
• Shen GX. Selective protein kinase C inhibitors and their applications. Curr Drug Targets 2003;3:301-7
   Google Scholar
• Kamran G, Arian L, John JO. Selectivity and therapeutic inhibition of kinases: to be or not tobe? Nat Immunol 2009;10:356-60
   PubMed Web of Science ®Google Scholar
• Charles LS. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010
   PubMed Web of Science ®Google Scholar
• Novartis Pharma GMBH. Use of PKC inhibitors in diabetic complications. W0200081000484A1; 2008
   Google Scholar
• Novartis AG and Novartis Pharma GmbH. Use of PKC inhibitors in particular indolylmaleimide derivatives in ocular diseases. WO2008024734A2; 2008
   Google Scholar
• Boehringer Ingelheim International GmbH. Pyridine derivatives useful as inhibitors of PKC-theta. US7468382B2; 2008
   Google Scholar
• Novartis AG. Indolylmaleimide derivatives as PKC inhibitors. US20080242675A1; 2008
   Google Scholar
• The Board of Trustees of the Leland Stanford Junior University. Peptide inhibitors of protein kinase C. US7393835 B2; 2008
   Google Scholar
• Pfizer, Inc. 3-amino-pyrrolo [3, 4-C] pyrazole- 5 (1H, 4H, 6H) carbaldehyde derivatives as PKC inhibitors. WO2008096260; 2008
   Google Scholar
• Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pyrimidine derivatives useful as inhibitors of PKC-theta. US7,550,473B2; 2009
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta. US7601714B2; 2009
   Google Scholar
• Janssen Pharmaceutica N.V. (BE). Substituted Pyrroline Kinase Inhibitors. US7488826B2; 2009
   Google Scholar
• Novartis Corporate Intellectual Property One Health Plaza. Pharmaceutical combination composition comprising at least one pkc inhibitor and at least one jak3 kinase inhibitor for treating autoimmune disorders. US10062301A1; 2009
   Google Scholar
• Novartis Corporate Intellectual Property One Health Plaza. Use of midostaurin for treating related gastrointestinal stromal tumors. US 20090075972 A1; 2009
   Google Scholar
• Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors. WO2009012421A1; 2009
   Google Scholar
• Saliwanchik lloyd & Saliwanchik. Protein kinase c as a target for the treatment of respiratory syncytial virus. US10226423A1; 2009
   Google Scholar
• Eder JP, Garcia CR, Clark JW, et al. A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs 2004;22:139-50
   PubMed Web of Science ®Google Scholar
• Cynthia XM, Matthew JC, Gina RP, et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 2013;137:483-92
   PubMed Web of Science ®Google Scholar
• Paula MF, Kerry JW, Ronald CC, et al. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 2011;67:1225-37
   PubMed Web of Science ®Google Scholar
• Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001;19:1485-92
   PubMed Web of Science ®Google Scholar
• Monnerat C, Henriksson R, Le Chevalier T, et al. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 2004;15:316-23
   PubMed Web of Science ®Google Scholar
• Martiny-Baron G, Kazanietz MG, Mischak H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem 1993;268:9194-7
   PubMed Web of Science ®Google Scholar
• Youn JS, Bok KO, Kang HK, et al. Protein kinase Cα/β inhibitor Gö6976 promotes PC12 cell adhesion and spreading through membrane recruitment and activation of protein kinase Cδ. Exp Cell Res 2013;319:153-60
   PubMed Web of Science ®Google Scholar
• Gekeler V, Boer R, Uberall F, et al. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF109203X on P-glycoprotein-mediated multidrug resistance. Br J Cancer 1996;74:897-905
   PubMed Web of Science ®Google Scholar
• Wilkinson SE, Parker PJ, Nixon JS. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J 1993;294:335-7
   PubMed Web of Science ®Google Scholar
• Aiello LP, Vignati L, Sheetz MJ, et al. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the protein kinase C β inhibitor-diabetic retinopathy study and the protein kinase C β inhibitor-diabetic retinopathy study 2. Retina 2011;10:2084-94
   Google Scholar
• Luis PA, Jean YD, Piotr K, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non–small-cell lung cancer. J Clin Oncol 2006;24:1428-34
   PubMed Web of Science ®Google Scholar
• Miguel AV, Paul R, Jose AF, et al. A Phase I/II study of LY900003, an antisense inhibitor of protein kinase C- α, in combination with cisplatin and gemcitabine in patients with advanced non–small cell lung cancer. Clin Cancer Res 2004;10:6086-93
   PubMed Web of Science ®Google Scholar
• Cripps MC, Figueredo AT, Oza AM, et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res 2002;8:2188-92
   PubMed Web of Science ®Google Scholar